



MIEBO is the ONLY Rx eye drop that directly targets a leading cause of DED—excessive tear evaporation due to MGD¹⁻⁷

An Rx drop with demonstrated efficacy and an excellent safety profile across 2 pivotal trials

Fast and lasting relief^{1,3,4,8*}

- Patients experienced **significant improvement** in the signs and symptoms of DED **at ~2 weeks**, with continued improvement through ~8 weeks (the end of the trials)
 - **2x improvement** vs hypotonic saline (control) in total corneal fluorescein staining (tCFS) at ~8 weeks[†]
 - **1.5x improvement** vs control in eye dryness (VAS) at ~8 weeks[†]
- **100% of patients had evidence of evaporative DED, with clinical signs of MGD present at enrollment**

Excellent tolerability^{1,3,4,8,9§}

- **No incidences** of serious ocular adverse events (AEs)
- **Low discontinuation rate** due to AEs (0.2%)
- **Low rate of burning or stinging** (0.5%)
- **One ocular AE** with an **incidence ≥2.0%** (blurred vision, 2.1%)

See pages 2-3 for results from an in vitro study evaluating evaporation rates with MIEBO

CFB, change from baseline; DED, dry eye disease; MGD, meibomian gland dysfunction; SD, standard deviation; VAS, Visual Analog Scale.

***Study design:** Two 57-day, multicenter, double-masked, saline-controlled studies (GOBI and MOJAVE) were conducted in adults ≥18 years old with a self-reported history of DED in both eyes and clinical signs of MGD. Primary endpoints were change from baseline in tCFS and change from baseline in eye dryness score (VAS) at Day 57. **Day 15 was the earliest time point at which signs and symptoms were evaluated in the trials, and Day 57 was the last.**^{1,3,4}

[†]**GOBI:** Mean (SD) CFB -2.0 (2.6) for MIEBO (n = 289) vs -1.0 (2.7) for control (n = 279) (P<0.001) at Day 57. **MOJAVE:** Mean (SD) CFB -2.3 (2.8) for MIEBO (n = 302) vs -1.1 (2.9) for control (n = 296) (P<0.001) at Day 57.^{1,3,4}

[†]**GOBI:** Mean (SD) CFB -27.4 (27.9) for MIEBO (n = 289) vs -19.7 (26.7) for control (n = 279) (P<0.001) at Day 57. **MOJAVE:** Mean (SD) CFB -29.5 (28.6) for MIEBO (n = 302) vs -19.0 (27.2) for control (n = 296) (P<0.001) at Day 57.^{1,3,4}

[§]Data were pooled from >1200 total patients from 2 pivotal clinical studies (GOBI and MOJAVE). Of the 614 patients who received MIEBO, there were no incidences of serious ocular AEs with MIEBO. Most AEs were considered mild. The discontinuation rate for MIEBO due to AEs was comparable to control (pooled: 0.2% vs 0.5%; GOBI: 0.3% vs 1.0%; MOJAVE: 0% vs 0%). 0.5% (pooled) of patients experienced instillation site pain AEs, such as burning or stinging (GOBI: 1.0%; MOJAVE: 0%). Blurred vision (pooled: 2.1%; GOBI: 3.0%; MOJAVE: 1.3%) and conjunctival redness (pooled: 0.8%; GOBI: 0%; MOJAVE: 1.3%) were reported in 1% to 3% of patients.^{1,3,4,8,9}

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.


IMPORTANT SAFETY INFORMATION

- MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO

Please see additional Important Safety Information throughout.
Please see full Prescribing Information for MIEBO at MIEBO-ECP.COM.

In an in vitro study, MIEBO inhibited evaporation more effectively than artificial tears or human meibum¹⁰

Mean Evaporation Rates of Saline With Artificial Tears or MIEBO*



MIEBO significantly INHIBITED THE EVAPORATION RATE of saline, unlike artificial tears

- At 100 µL, MIEBO inhibited the evaporation rate of saline by 81% ($P < 0.0001$)
- The addition of various artificial tear eye drops at 100 µL had no influence on the evaporation rate (R_{evap}) of saline ($P \geq 0.13$ vs saline alone)

**The clinical significance of this data has not been established.
The exact mechanism of action for MIEBO in DED is not known.¹**

Study design: The R_{evap} of saline was measured following application of either MIEBO or different OTC artificial tears. The R_{evap} was measured gravimetrically at 25 °C using an analytical balance after layering 100 µL of MIEBO or artificial tears on the surface of 1 mL of saline in a container with a surface area similar to that of the human ocular surface. Evaporation rates are presented as standard error of the mean (SEM).¹⁰

All brand names and trademarks used herein are the property of their respective owners; Systane Ultra (Alcon, Fort Worth, Texas), Systane Balance (Alcon, Fort Worth, Texas), Soothe XP (Bausch + Lomb, Bridgewater, New Jersey). **No clinical efficacy is implied.**

*Numbers in parentheses are the number of determinations. P values to test for significance vs saline alone were measured using the t test.¹⁰


IMPORTANT SAFETY INFORMATION (CONTINUED)

- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established

**Please see additional Important Safety Information throughout.
Please see full Prescribing Information for MIEBO at MIEBO-ECP.COM.**

Miebo[®]
(perfluorohexyloctane
ophthalmic solution)

Mean Evaporation Rates of Saline With Meibum Lipids and/or MIEBO*



MIEBO was
4x MORE EFFECTIVE
at inhibiting evaporation
vs meibum lipids

- There was no significant difference between the R_{evap} of saline with only MIEBO layered on top compared with both meibum lipids and MIEBO layered on top ($P > 0.5$)

**The clinical significance of this data has not been established.
The exact mechanism of action for MIEBO in DED is not known.¹**

Study design: The inhibitory effect of MIEBO vs meibum on the R_{evap} of saline was evaluated in an in vitro model. Meibum lipids were collected from a single healthy volunteer. The R_{evap} of saline was measured gravimetrically at 35 °C after layering either a single drop of MIEBO or the collected human meibum lipids to approximate the tear lipid layer in vivo over the top of 1 mL saline in a plastic container with a surface area approximating that of the human ocular surface. Evaporation rates are presented as SEM.¹⁰

*Percentage values are percent inhibition of the R_{evap} of saline. Numbers in parentheses are the number of determinations. *P* values to test for significance were measured using the *t* test.¹⁰

MIEBO contains 1 active ingredient—it's 100% perfluorohexyloctane with NO vehicle¹

IMPORTANT SAFETY INFORMATION (CONTINUED)

- In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

**Please see additional Important Safety Information throughout.
Please see full Prescribing Information for MIEBO at MIEBO-ECP.COM.**

Miebo[®]
(perfluorohexyloctane
ophthalmic solution)

How MIEBO works

MIEBO spreads quickly and evenly to form a protective layer on the ocular surface, preventing tear evaporation^{1,2,10-12}

The exact mechanism of action for MIEBO in DED is not known.¹



Mimics key functions of natural meibum and helps stabilize the tear film^{1,2,10,12,13}



Promotes healing on the ocular surface^{1,9}



May reduce friction^{3,4,14}



Want to learn more about MIEBO?
Visit [MIEBO-ECP.COM](https://www.miebo-ecp.com)



IMPORTANT SAFETY INFORMATION

- MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Please see full Prescribing Information for MIEBO at [MIEBO-ECP.COM](https://www.miebo-ecp.com).

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. MIEBO. Prescribing Information. Bausch & Lomb, Inc. 2. Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. *Ophthalmol Ther.* 2023;12(3):1397-1418. doi:10.1007/s40123-023-00669-1 3. Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. *Ophthalmology.* 2023;130(5):516-524. doi:10.1016/j.ophtha.2022.12.021 4. Sheppard JD, Kurata F, Epitropoulos AT, Krösser S, Vittitow JL; MOJAVE Study Group. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. *Am J Ophthalmol.* 2023;252:265-274. doi:10.1016/j.ajo.2023.03.008 5. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea.* 2012;31(5):472-478. doi:10.1097/ICO.0b013e318225415a 6. Rabensteiner DF, Aminfar H, Boldin I, et al. The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. *Acta Ophthalmol.* 2018;96:e707-e711. doi:10.1111/aos.13732 7. Badian RA, Utheim TP, Chen X, et al. Meibomian gland dysfunction is highly prevalent among first-time visitors at a Norwegian dry eye specialist clinic. *Sci Rep.* 2021;11(23412):1-8. doi:10.1038/s41598-021-02738-6 8. Fahmy AM, Harthan JS, Evans DG, et al. Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials. *Front Ophthalmol (Lausanne).* 2024;4:1452422. doi:10.3389/fopht.2024.1452422 9. Data on file. Bausch & Lomb, Inc. 10. Vittitow J, Kissling R, DeCory H, Borchman D. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. *Curr Ther Res Clin Exp.* 2023;98:100704. doi:10.1016/j.curtheres.2023.100704 11. Meinert H, Roy T. Semifluorinated alkanes – a new class of compounds with outstanding properties for use in ophthalmology. *Eur J Ophthalmol.* 2000;10(3):189-197. doi:10.5301/EJO.2008.1838 12. Agarwal P, Khun D, Krösser S, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. *Ocul Surf.* 2019;17(2):241-249. doi:10.1016/j.jtos.2019.02.010 13. Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: Management and therapy. *Am J Ophthalmol.* 2025;279:289-386. doi:10.1016/j.ajo.2025.05.039 14. Schmid D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. *J Ocul Pharmacol Ther.* 2020;36(3):154-161. doi:10.1089/jop.2019.0092

BAUSCH + LOMB

©2026 Bausch + Lomb
MBO.0519.USA.25

Miebo
(perfluorohexyloctane
ophthalmic solution)